Now Is the Time to Reconsider: Repros Therapeutics Inc. (RPRX)
Окт 12 2017 by Johnny Bowman
Analytical Significance of Simple Moving Average for Repros Therapeutics Inc.
Looking into last 5 trades, the stock observed a return of nearly 131.48%. Its opening price on the last trading day was $0.53. The firm's market capitalization is $14.81 million. With short interest at 811,786 and short average daily volume at 330,648, the short-interest ratio is 2.0 and the short interest percentage is 0.03% as of September 15. The share last price represents downtick move of -65.60% in value from company's 52-Week high price and shows 188.46% above change in value from its 52-Week low price. The company rocked its 52-Week High of $2.16 and touched its 52-Week Low of $0.26. (NASDAQ:ITUB) posting a -1.39% after which it closed the day' session at $14.14 and the company has experienced volume of 6,397,926 shares while on average the company has a capacity of trading 10.24M share while its relative trading volume is 0.63.
Repros Therapeutics Inc. (RPRX) stock directed -64.62% toward a lower level throughout a year ago and swapped 149.58% toward a strong spot during past one month.
By taking a look at the stock's current statistics it can gauged that the stock candle is BULLISH with HIGH volatility. The stock's quarterly performance indicates a negative momentum of -0.75 percent, whereas its last one month trend is optimistic with 76.49 percent.
Profitability analysis helps a great deal in making investment decision. AT&T Inc. has 6.14 billion shares outstanding, and in the last trade has seen ATR around 0.53. Short-term as well long term investors always focus on the liquidity of the stocks so for that concern, liquidity measure in recent quarter results of the company was recorded 2.60 as current ratio and on the opponent side the debt to equity ratio was 0.29 and long-term debt to equity ratio also remained 0.27.
The stock has Return on Assets (ROA) of -212.1 percent. Moving averages are used as a strong indicator for technical stock analysis and it helps investors in figuring out where the stock has been and also facilitate in determining where it may be possibly heading. The average true range is a moving average, generally 14 days, of the true ranges.
EPS Estimate for the next year is -1.01. Analysts are forecasting earnings of $-0.28 on a per share basis this quarter. However, YTD EPS growth remained -30.89%. Next year this decline will reach 0%.
Looking forward, the company's quarterly earnings in the three months through September 2017 and in the quarter ending December 2017, reflecting -587747% and -624475% growth, respectively. A low ROE warns that the company is not generating a good return on its reinvested earnings. The company P/S (price to Sales) ratio is 0, P/B (price to Book) ratio is 0, while its P/C (price to Cash) ratio stands at 5.07.
Social Reality, Inc. (NASDAQ:SRAX) is worth US$27.13 Million and has recently risen 38.4% to US$3.28.
The clinical development expenses pertaining to enclomiphene dropped for the reported quarter as against the prior year period, due to lower expenses related with its Phase II proof of concept trial, ZA-205. Repros Therapeutics (RPRX) now has a 14-day Commodity Channel Index (CCI) of 198.55.
Currently Repros Therapeutics (NASDAQ:RPRX)'s shares owned by insiders are 0.2%, whereas shares owned by institutional owners are 20.1%.
При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна. «» 2007 - 2017 Copyright. Автоматизированное извлечение информации сайта запрещено.